Abstract Respiratory Syncytial Virus (RSV) infection is the leading cause of lower respiratory
tract infection in both young children and older adults. Currently, there is no licensed vaccine …

Infection with Respiratory Syncytial Virus (RSV) causes both upper and lower respiratory
tract disease in humans, leading to significant morbidity and mortality in both young children …

Respiratory syncytial virus (RSV) is the leading, global cause of serious respiratory disease
in infants and is an important cause of respiratory illness in older adults. No RSV vaccine is …

Respiratory syncytial virus (RSV) is a highly contagious virus causing severe infection in
infants and the elderly. Various approaches are being used to develop an effective RSV …

Background The respiratory syncytial virus (RSV) fusion glycoprotein (F) is a molecule that
fuses the viral and host cell membranes during virus entry as it rearranges from a meta …

Respiratory syncytial virus (RSV) is the leading cause of hospitalization for children under 5
years of age. We sought to engineer a viral antigen that provides greater protection than …

Respiratory syncytial virus (RSV) causes acute lower respiratory tract infections and is the
leading cause of infant hospitalizations. Recently, a promising vaccine antigen based on the …

Highlights•RSV is an important cause of lower respiratory tract infection and disease at the
extremes of age.•The RSV fusion (F) glycoprotein is the major target for virus neutralizing …

Respiratory syncytial virus (RSV) infection causes significant disease in the lower respiratory
tract of young children, and there is currently no licensed vaccine to prevent RSV infection …

Efforts to develop a vaccine for respiratory syncytial virus (RSV) have primarily focused on
the RSV fusion protein. The pre-fusion conformation of this protein induces the most potent …